CommercialCoverageMedium impact
05.00.77f, Implantable Cardioverter Defibrillators
Independence Blue Cross·Cardiology, Cardiothoracic Surgery, Critical Care +1 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated policy 05.00.77f to 05.00.77g, expanding coverage to include transvenous, subcutaneous, and extravascular implantable cardioverter defibrillators (ICDs). The policy clarifies medical necessity criteria for primary prevention across multiple cardiac conditions and explicitly excludes extravascular ICDs as experimental/investigational. Billing teams must ensure claims are coded correctly and that extravascular ICD claims are denied per policy.
Action Required
By April 1, 2026: Billing team must update systems to recognize the new policy version 05.00.77g. (1) Verify that all ICD procedure codes (33216-33241) and device codes (C1721, C1722, C1895, C1896) are mapped to the updated medical necessity criteria listed in the policy for transvenous and subcutaneous ICDs. (2) Configure billing system to automatically DENY any claims for extravascular ICDs (code not specified in policy) with denial message: 'Extravascular ICD is experimental/investigational and not covered.' (3) Update prior authorization templates to require documentation of NYHA functional class, LVEF percentage, MI history timeline, and specific diagnosis from the covered conditions list (ischemic/nonischemic cardiomyopathy, HCM, ion channelopathies, cardiac sarcoid). (4) Train billing and authorization staff on the six primary prevention indications and exclusion criteria (e.g., PCI/CABG within 90 days, MI within 40 days, NYHA Class IV). (5) Update encounter forms and EMR templates to prompt providers to document which specific coverage criterion applies. Failure to implement denial logic for extravascular devices will result in claim denials on appeal; claims lacking required documentation will be denied for insufficient medical necessity.